Brazil steps closer to reagents self-reliance
This article was originally published in Clinica
Brazilian efforts to develop low-cost diagnostic reagents took a major step forward yesterday, with the approval of further funding for the R$106m (US$55m) centre that will house the country's largest production facility. The national development bank (BNDES) has committed R$30m to building the "integrated centre for prototypes, biopharmaceuticals and reagents" (CIPBR), which is scheduled to come into operation in 2009, as part of the Fiocruz foundation's Biomanguinhos biologics R&D division.
You may also be interested in...
Early results from the Low-Risk Bicuspid study of the Evolut transcatheter aortic valve replacement system showed low rates of all-cause mortality or stroke.
The reality is that many trials requiring hospital based tests and interventions cannot be replaced, but crisis will spur take up where practical.
The two companies announced more details about their COVID-19 vaccine development plan, including a $185m upfront payment and $113m equity investment from Pfizer.